Ascendis Pharma A/S (ASND)
| Market Cap | 8.96B |
| Revenue (ttm) | 6.02M |
| Net Income (ttm) | -545.09M |
| Shares Out | 56.84M |
| EPS (ttm) | -10.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,509 |
| Open | 158.48 |
| Previous Close | 157.72 |
| Day's Range | 156.98 - 169.84 |
| 52-Week Range | 109.36 - 183.98 |
| Beta | 0.80 |
| Analysts | Strong Buy |
| Price Target | 195.76 (+16.3%) |
| Est. Earnings Date | Nov 10, 2021 |
About ASND
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorpo...
Financial Performance
In 2020, ASND's revenue was 6.95 million, a decrease of -48.01% compared to the previous year's 13.38 million. Losses were -418.96 million, 92.2% more than in 2019.
Financial numbers in millions EURFinancial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ASND stock is "Strong Buy." The 12-month stock price forecast is 195.76, which is an increase of 16.32% from the latest price.
News
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Cont...
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Ascendis Pharma A/S Announces Upcoming Investor Presentations
COPENHAGEN, Denmark, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
– TransCon IL-2 β/γ is an investigational long-acting prodrug designed to improve cancer immunotherapy through the sustained systemic release of an IL-2 variant with potential for prolonged activation ...
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new trea...
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
COPENHAGEN, Denmark, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treat...
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – ...
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
Why Shares of Ascendis Soared This Week
The pharmaceutical company saw its shares jump more than $26.
Here's Why Ascendis Pharma Shares Are Surging Higher Today
Approval of the company's weekly growth hormone is making investors smile today.
See Why Ascendis Pharma Stock Is Shining On Thursday
The FDA on Wednesday gave a thumbs-up to Ascendis Pharma A/S's (NASDAQ: ASND) long-acting growth hormone lonapegsomatropin-tcgd. Marketed as Skytrofa, the somatropin prodrug has been approved in kids ag...
These 2 Stocks Soared Double Digits After Hours
Find out where the big winners were late Wednesday.
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results
– Announced U.S. Food and Drug Administration Approval of SKYTROFA ® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency –
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the F...
- SKYTROFA, the first FDA approved treatment utilizing TransCon™ technology, is a long-acting prodrug of somatropin that releases the same somatropin used in daily therapies –
Is a Surprise Coming for Ascendis Pharma (ASND) This Earnings Season?
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
All it will take is an FDA approval and a partial repeat of history.
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
COPENHAGEN, Denmark, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates th...
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
COPENHAGEN, Denmark, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create new product candidate...
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months
The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the treatment of pediatric growth hormone deficiency. Ci...
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapeg...
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 Prescription Drug User Fee Act (PDUFA) goal date extended by three months...
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China...
What 5 Analyst Ratings Have To Say About Ascendis Pharma
Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 0 2 0 1 Indifferent ...
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of W...
Online event to include a live reading by Children's Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards Online event to include a live reading by Ch...
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
– Pre-launch activities continue in preparation for a potential FDA approval of TransCon™ hGH (lonapegsomatropin) for pediatric growth hormone deficiency; PDUFA date of June 25, 2021 –